loading page

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development
  • +3
  • Nasir Akbar Mir,
  • Kapil Dev,
  • Bidyarani Buyamayum,
  • Mohd Yaqoob Wani,
  • Meesam Raza
Govind Ballabh Pant University of Agriculture & Technology College of Veterinary & Animal Sciences

Corresponding Author:[email protected]

Author Profile
Nasir Akbar Mir
Central Avian Research Institute
Author Profile
Kapil Dev
Central Avian Research Institute
Author Profile
Bidyarani Buyamayum
Jawaharlal Nehru Institute of Medical Sciences Department of Microbiology
Author Profile
Mohd Yaqoob Wani
Sher-E-Kashmir University of Agricultural Sciences and Technology Faculty of Veterinary Sciences and Animal Husbandry
Author Profile
Meesam Raza
Central Avian Research Institute
Author Profile


The outbreak of COVID-19 as a pandemic has shaken the global health system and economy by their roots. This epidemic is still spreading and showing no signs of decreasing trend. Vaccination is the only effective and economical means to control this pandemic. A number of research institutions and pharmaceutical companies have plunged into the race of vaccine development against COVID-19 which are in various stages of development. An intriguing fact of coronavirus infections is that in every decade of 21st century there is a new major coronavirus epidemic viz. SARS in 2002, MERS in 2012, and now COVID-19; and such epidemics are expected in future too. Since, maximum biological characteristics of SARS-CoV-2 are still obscure the scientists are relying on the information available on SARS-CoV and to some extent on MERS-CoV for designing and development of COVID-19 vaccines. But there is a need of vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts. This review focuses on the challenges and prospects of vaccine development against COVID-19. It highlights seriousness, bottlenecks in vaccine development, possible vaccine candidates, different vaccine strategies, safety evaluation issues, and vaccine production process pertaining to COVID-19 based on the knowledge acquired on SARS and MERS vaccine development in the past.
20 May 2020Submitted to Transboundary and Emerging Diseases
21 May 2020Submission Checks Completed
21 May 2020Assigned to Editor
23 May 2020Reviewer(s) Assigned
10 Jul 2020Review(s) Completed, Editorial Evaluation Pending
13 Jul 2020Editorial Decision: Revise Major
14 Jul 20201st Revision Received
15 Jul 2020Assigned to Editor
15 Jul 2020Submission Checks Completed
15 Jul 2020Reviewer(s) Assigned
14 Aug 2020Review(s) Completed, Editorial Evaluation Pending
14 Aug 2020Editorial Decision: Revise Minor
14 Aug 20202nd Revision Received
15 Aug 2020Assigned to Editor
15 Aug 2020Submission Checks Completed
15 Aug 2020Review(s) Completed, Editorial Evaluation Pending
15 Aug 2020Editorial Decision: Accept
May 2021Published in Transboundary and Emerging Diseases volume 68 issue 3 on pages 1111-1124. 10.1111/tbed.13804